Dror Bashan - 01 Apr 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Dror Bashan
Issuer symbol
PLX
Transactions as of
01 Apr 2023
Net transactions value
$0
Form type
4
Filing time
03 Apr 2024, 17:30:27 UTC
Previous filing
09 Sep 2022
Next filing
17 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLX Common Stock Award +263,960 +14% 2,149,418 01 Apr 2024 By Trust F1, F2
holding PLX Common Stock 132,516 01 Apr 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan").
F2 To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.